Mon May 12 07:10:00 UTC 2025: ## Bavarian Nordic Reports Strong Q1 2025 Results, Driven by Travel Health and Public Preparedness
**COPENHAGEN, Denmark (May 9, 2025)** – Bavarian Nordic A/S (OMX: BAVA), a global vaccine company, today announced impressive first-quarter 2025 financial results, exceeding expectations in both its Travel Health and Public Preparedness divisions.
The company reported a 52% year-over-year growth in its Travel Health business, surpassing its projected annual growth rate of 10-12% through 2027. This strong performance was driven by increased sales of its existing travel vaccines. Furthermore, Bavarian Nordic announced its first US sales of its chikungunya vaccine following its February approval, ahead of the April recommendation from the Advisory Committee on Immunization Practices (ACIP). The company is implementing a phased launch plan, with expansion into European markets expected in the coming months, and ongoing efforts to secure further regulatory approvals globally. A key achievement in this area involves a new partnership to increase access to the chikungunya vaccine in low- and middle-income countries.
The Public Preparedness division also delivered results above projections, primarily due to accelerated vaccine deliveries. This success underscores the company’s robust manufacturing capabilities and capacity to meet growing demand for its mpox/smallpox vaccine (JYNNEOS®). Bavarian Nordic also announced securing the manufacturing and supply of freeze-dried JYNNEOS® to the U.S. in 2026.
Bavarian Nordic’s CEO, Paul Chaplin, expressed his satisfaction with the strong first-quarter performance and highlighted the company’s commitment to expanding its vaccine portfolio and improving global health. A conference call for investors and analysts is scheduled for today at 2 pm CEST (8 am EDT) to discuss the results in detail.
First Piper 